About Us

Developing the Next-Generation Cancer Therapies

Rexahn Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of cancer. Our mission is to extend and improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects normally associated with cancer treatment.

The Rexahn Approach

Rexahn is focused on discovering and developing new treatments that have the potential to improve the clinical outcome in cancers that are difficult to treat. Through targeting cancer therapies to tumor cells, we aim to minimize effects on healthy tissue and improve safety and quality of life relative to other treatment options.

We believe that optimum anticancer efficacy will be achieved through using combinations of drugs that work in different ways to kill cancer cells and inhibit tumor growth. Rexahn's targeted therapies act synergistically with other anticancer agents and with immunotherapy in preclinical models. We are currently evaluating the combination approach in our clinical studies.

The Fight Against Cancer


American lives are claimed by cancer every year, according to the Centers for Disease Control and Prevention.


Deaths in 2015 were caused by cancer, according to a survey done by the World Health Organization in 2018.


New cancer cases will be diagnosed in the United States in 2018, according to a 2018 report by the American Cancer Society.

Product Pipeline

Rexahn has two oncology product candidates, RX-3117 and RX-5902, in Phase 2 clinical development and additional compounds in preclinical development including RX-0301. Our product candidates work by targeting and neutralizing specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth, proliferation and metastasis.

Candidate & Indication Collaborators Preclinical Phase 1 Phase 2


Metastatic Pancreatic Cancer

Advanced Bladder Cancer

Preclinical complete
Preclinical complete
Phase 1 complete
Phase 1 complete
Phase 2 in progress
Phase 2 in progress


Metastatic Triple Negative Breast Cancer

Merck & Co.
Preclinical complete
Phase 1 complete
Phase 2 in progress


Hepatocellular Carcinoma

Preclinical in progress
Phase 1 not started
Phase 2 not started


A Novel Small Molecule Nucleoside Analogue Targeted to Cancer Cells

RX-3117 is a novel, oral small molecule nucleoside compound being developed for the treatment of metastatic pancreatic cancer and advanced bladder cancer. RX-3117 is a prodrug that is activated in tumor cells by a kinase, UCK2. The targeted activation offers the potential for better efficacy and safety relative to older nucleoside analogues.

View RX-3117


First-in-Class Small Molecule Modulator of the β-catenin/Wnt Pathway

RX-5902 modulates the activity of the β-catenin/Wnt pathway which is a key pathway involved in cancer cell growth and proliferation, oncogene expression and activation of the immune response against cancer. RX-5902 modulates the pathway through inhibition of phosphorylated p68 which is over expressed in tumor cells. RX-5902 is in Phase 2 clinical trials for triple negative breast cancer (TNBC) and will also be evaluated in combination with Keytruda® (pembrolizumab) for TNBC in collaboration with Merck.

View RX-5902